Drug approved for rheumatoid arthritis successfully treats a patient with disfiguring sarcoidosis, a chronic disease that can affect various organs, reports a new study. The findings of the study are published in the New England Journal of Medicine.
Successful treatment of two other patients with similarly severe disease suggests an effective treatment for an incurable; sometimes life-threatening illness is within reach, the scientists said.
Sarcoidosis / Besnier - Boeck disease
Bernie Mac the comedian died of complications arising from Sarcoidosis, a little known immune system disorder.
Advertisement
‘Sarcoidosis is an inflammatory disease which alters the immune system and affects multiple organs in the body. It can cause disfiguring lesions on the skin. But a new study finds that an existing rheumatoid arthritis drug can cure this potentially life-threatening condition.’
Read More..
Tweet it Now
Read More..
Sarcoidosis is an inflammatory disease that affects multiple organs in the body. While some sarcoidosis patients recover without treatment, others suffer damage to the lungs, heart, lymph nodes, skin, and other organs. Current treatments, including steroids, are not reliably effective for the skin and can cause serious side effects.
Based on clues gleaned from prior studies, the Yale team decided to try the arthritis medication tofacitinib. The drug, a Jak inhibitor, blocks a pathway known as Jak-STAT. The lead author, Brett King, M.D., has pioneered the use of Jak inhibitors to treat other intractable skin diseases, including vitiligo, alopecia areata, and eczema.
![Procedures for Diagnosing Sarcoidosis Evaluated By Study]( "Procedures for Diagnosing Sarcoidosis Evaluated By Study")
Among patients with suspected stage I/II pulmonary sarcoidosis, the use of the procedure known as endosonographic nodal aspiration resulted in greater diagnostic yield.
For several months, a 48-year-old female patient was treated with the drug, a twice-daily pill. The researchers observed that her skin lesions nearly disappeared. They also performed RNA sequencing on biopsied skin from the patient before and during treatment. "Before treatment, we were able to show that the Jak-STAT pathway is activated," King said. "During treatment, not only does her skin disease go away, but there is no activation of the pathway."
"We plan to evaluate the activation of the Jak-STAT pathway in the lung fluid and blood of over 200 patients with pulmonary and multiorgan sarcoidosis," said co-author Nkiruka Emeagwali. These are big steps toward understanding a disease that has been a mystery for years, the researchers said.
The findings are being tested further by the Yale team in a clinical trial. If confirmed, they could represent a breakthrough for sarcoidosis patients, King noted.
"A frequently awful disease, which to date has no reliably effective therapy, may now be targeted with Jak inhibitors," he said. "We have a relatively safe medicine that works."
Other Yale authors are William Damsky, Durga Thakral, and Anjela Galan.
Source: Eurekalert
Procedures for Diagnosing Sarcoidosis Evaluated By Study
Among patients with suspected stage I/II pulmonary sarcoidosis, the use of the procedure known as endosonographic nodal aspiration resulted in greater diagnostic yield.
Advertisement
For several months, a 48-year-old female patient was treated with the drug, a twice-daily pill. The researchers observed that her skin lesions nearly disappeared. They also performed RNA sequencing on biopsied skin from the patient before and during treatment. "Before treatment, we were able to show that the Jak-STAT pathway is activated," King said. "During treatment, not only does her skin disease go away, but there is no activation of the pathway."
"We plan to evaluate the activation of the Jak-STAT pathway in the lung fluid and blood of over 200 patients with pulmonary and multiorgan sarcoidosis," said co-author Nkiruka Emeagwali. These are big steps toward understanding a disease that has been a mystery for years, the researchers said.
The findings are being tested further by the Yale team in a clinical trial. If confirmed, they could represent a breakthrough for sarcoidosis patients, King noted.
"A frequently awful disease, which to date has no reliably effective therapy, may now be targeted with Jak inhibitors," he said. "We have a relatively safe medicine that works."
Other Yale authors are William Damsky, Durga Thakral, and Anjela Galan.
Source: Eurekalert
Mold Exposure Ups Risk for Sarcoidosis
Mold exposure at homes could boost risk for sarcoidosis, a chronic inflammatory lung disease, say researchers.
Advertisement
Advertisement
|
Advertisement
